The European Medicines Agency EMA will leave London and relocate to Amsterdam because of Brexit, which is announced for 29 March 2019. Accomplishing this change of location without massive operational restrictions is an enormous task and detailed planning has already commenced. EMA has published an interactive tool the interested public can use to track the progress of the various relocation preparations. This interactive PDF document indicates the milestones scheduled for the relocation, the progress already made, and whether there are delays to the schedule.

The Amendment of the German Medicinal Products Act [Arzneimittelgesetz – AMG] enters into force
The Clinical Trials Regulation, Regulation EU No 536/2014 is expected to come into application in 2019. This regulation is intended to further harmonise the approval, conduct and monitoring of clinical trials in the EU, and to replace the current Clinical Trials Directive 2001/20/EC. Since an EU regulation (unlike an EU directive) is directly applicable law in all EU member states, the German Medicinal Products Act (AMG) had to have certain rules that do not comply with the new EU Regulation removed. In addition, national regulations had to be defined for those areas in which the EU Clinical Trials Regulation still leaves the Member States some room for manoeuvre.

Sorry, this page is not available in English.

If you want to learn more about the suspected fraud in clinical trials on generic drugs in India, please contact us.

Sorry, this page is not available in English.

If you want to learn more about the fatal accident in a phase I clinical trial in Rennes (Frabnce) in 2016, please contact us.

Sorry, this page is not available in English.

If you want to learn more about the German puplic databases on non-interventional studies, please contact us.